Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

TD Cowen raised the firm’s price target on Ally Financial (ALLY) to $41 from $40 and keeps a Buy rating on the shares. The firm said the Q4 ...

TD Cowen analyst Moshe Orenbuch maintained a Buy rating on SLM (SLM – Research Report) today and set a price target of $33.00. The company’s ...

This month, in the Wasatch Mountains of Utah, the Sundance Film Festival is once again providing a showcase for independent ...

Analysts noted that if Ally Financial (NYSE:ALLY) can sustain the lower losses in its auto loan portfolio, this could hasten ...

Investing.com -- TD Cowen downgraded Celsius Holdings (NASDAQ:CELH) to Hold and slashed its price target for the stock to $29 from $40 in a note Wednesday, citing slowing sales growth ...

Investing.com -- LVMH is well-positioned for long-term success, despite some near-term challenges, according to analysts at TD Cowen. The bank maintains a positive outlook on the luxury giant ...

On Tuesday, Forte Biosciences Inc. (NASDAQ:FBRX), a biotech company with a market capitalization of approximately $100 million, received a new Buy rating from TD Cowen, as the firm ... insight into ...

While financial specifics remain unclear, TD Cowen described the Stargate venture as a “directional win-win” for both Oracle and Microsoft.

The rise in targets in recent days, however, pushes the stock toward $360 after UBS Group raised its target on Salesforce and maintained a "neutral" rating, and Needham & Company raised the price ...

LONDON, Ont. — Easton Cowan scored twice and added an assist to lead the league-leading London Knights to an 8-1 rout of the Sudbury Wolves.in Ontario Hockey League action Sunday. Cowan ...